IQVIA Biotech Thought Leadership

  1. Achieving Excellence In IO Clinical Trials 6/21/2023

    Immuno-oncology therapies have revolutionized the treatment of cancer patients worldwide. Learn how to plan for success and reduce risk when developing novel treatments for patients with cancer.

  2. DLBCL Asia-Pacific Insights And Experiences 6/21/2023

    Get an overview of trends and insights into the current development of DLBCL clinical trials in the APAC and excerpts from an expert panel discussion from eight APAC countries.

  3. Unlocking Europe's Commercial Potential For Biopharma Startups 6/21/2023

    Dive into this compelling case for launching emerging biopharma in Europe and how to succeed.

  4. Mitigating CAR Risks In Autologous CAR-T Therapy Trials In Oncology 6/21/2023

    Developed from a clinical trial perspective, consider these practices when managing toxicities associated with autologous Chimeric Antigen Receptor T-cell (CAR-T) therapies among patients with B-cell hematologic malignancies.

  5. The Shifting Paradigm Of Dose Selection In Oncology 6/21/2023

    Oncology drug development is undergoing a significant transformation. Explore strategies for integrating dose finding and optimization into early clinical development and how it could benefit oncology patients.

  6. Navigating An Evolving Global Regulatory Landscape 8/19/2021

    Our regulatory experts are closely following the evolution of regulatory guidance on COVID-19 and the approach taken by global regulatory agencies.

  7. Nuances Of Hematologic Oncology Clinical Trials 7/26/2021

    This paper examines the requirements for effectively and successfully conducting hematologic oncology clinical trials.

  8. Going Virtual: Yes, Oncology Trials Can Do It Too 8/19/2021

    How do patients receive necessary continued care when there is limited or no access to providers or trial sites? With the risk of exposure to COVID-19, will immunocompromised patients be safe to participate in trials in the traditional sense now and in the future?

  9. Natural History Studies For Rare Diseases: Development Strategies For External Comparator Arms Leveraging Real World Insights 7/26/2021

    This paper explores essential principles for defining the right strategy for natural history studies and how to design such studies in a way that the data can be used as an external comparator to augment future regulatory filings and payer submissions.

  10. Partnering Solutions For Emerging Biopharma 7/26/2021

    This paper is the first part of a series of articles aimed at helping the EBP team better assess the value of a “partnered” outsourcing approach across the continuum of development and commercialization, and potential approaches to mapping out the right fit for their organizational needs.